Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined why some cancer patients fail to respond to PD-1 checkpoint inhibitors, focusing on gut microbiome composition as a driver of primary resistance.
How was it studied?
The team analyzed antibiotic use and outcomes in advanced cancer patients on checkpoint inhibitors, then performed fecal microbiota transplantation from responding and nonresponding patients into germ-free or antibiotic-treated mice. They also profiled patient stool metagenomes at diagnosis and tested oral Akkermansia muciniphila supplementation.
What did they find?
Antibiotics blunted clinical benefit from checkpoint inhibitors. FMT from responders restored PD-1 blockade efficacy in mice, while FMT from nonresponders did not. Clinical response correlated with relative abundance of Akkermansia muciniphila, and supplementing nonresponder-FMT mice with this microbe restored antitumor efficacy in an interleukin-12-dependent manner by boosting CCR9+CXCR3+CD4+ T cell recruitment into tumors.
Why it matters
The findings suggest gut microbiome composition, and specifically Akkermansia muciniphila, may be modifiable factors influencing whether patients respond to PD-1 based immunotherapy.